Berberine hydrochloride IL-8 dependently inhibits invasion and IL-8-independently promotes cell apoptosis in MDA-MB-231 cells

• Published in: Oncology reports Vol. 32; no. 6; pp. 2777 - 2788
• Main Authors: LI, XIANG, ZHAO, SHU-JUAN, SHI, HAI-LIAN, QIU, SHUI-PING, XIE, JIAN-QUN, WU, HUI, ZHANG, BEI-BEI, WANG, ZHENG-TAO, YUAN, JIAN-YE, WU, XIAO-JUN
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.12.2014; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Apoptosis; Apoptosis - drug effects; Berberine - administration & dosage; berberine hydrochloride; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer therapies; Care and treatment; Cell adhesion & migration; Cell cycle; Cell growth; Cell Line, Tumor; Development and progression; Female; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Genetic aspects; Humans; interleukin-8; Interleukin-8 - genetics; Interleukin-8 - metabolism; Kinases; MAP Kinase Signaling System - genetics; MDA-MB-231 cells; Metastasis; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; NF-kappa B - genetics; p38 Mitogen-Activated Protein Kinases - genetics; Phosphatidylinositol 3-Kinases - genetics; Phosphorylation; proliferation; Proto-Oncogene Proteins c-akt - genetics; Signal Transduction - drug effects; Studies; Transcription Factor AP-1 - genetics; China; United States > US
• ISSN: 1021-335X; 1791-2431
• DOI: 10.3892/or.2014.3520

Breast cancer, the leading cause of cancer-related mortality worldwide in females, has high metastastic and recurrence rates. The aim of the present study was to evaluate the anti-metastatic and anticancer in situ effect of berberine hydrochloride (BER) in MDA-MB-231 cells. BER dose-dependently inhibited proliferation and the IL-8 secretion of MDA-MB-231 cells. Additional experiments revealed that the inactivation of PI3K, JAK2, NF-κB and AP-1 by BER contributed to the decreased IL-8 secretion. BER abrogated cell invasion induced by IL-8 accompanied with the downregulation of the gene expression of MMP-2, EGF, E-cadherin, bFGF and fibronectin. In addition, BER reduced cell motility but induced G2/M arrest and cell apoptosis in an IL-8-independent manner. BER modulated multiple signaling pathway molecules involved in the regulation of cell apoptosis, including activation of p38 MAPK and JNK and deactivation of JAK2, p85 PI3K, Akt and NF-κB. The enhanced cell apoptosis induced by BER was eliminated by inhibitors of p38 MAPK and JNK but was strengthened by activator of p38 MAPK. Thus, BER inhibited cell metastasis partly through the IL-8 mediated pathway while it induced G2/M arrest and promoted cell apoptosis through the IL-8 independent pathway. Apoptosis induced by BER was mediated by crosstalks of various pathways including activation of p38 MAPK and JNK pathways and inactivation of JAK2/PI3K/NF-κB/AP-1 pathways. The results suggested that BER may be an efficient and safe drug candidate for treating highly metastatic breast cancer.